Parasitology Research

, Volume 90, Supplement 2, pp S71–S76

Fosmidomycin for the treatment of malaria

Original Paper

DOI: 10.1007/s00436-002-0770-9

Cite this article as:
Wiesner, J., Borrmann, S. & Jomaa, H. Parasitol Res (2003) 90: S71. doi:10.1007/s00436-002-0770-9

Abstract.

In malaria parasites, isoprenoids are synthesised by the mevalonate independent 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. Fosmidomycin, a natural antibiotic originally developed for the treatment of bacterial infections, represents an inhibitor of DOXP reductoisomerase, an essential enzyme of this pathway. In recent clinical studies it was shown that fosmidomycin is effective in curing uncomplicated Plasmodiumfalciparum malaria in humans. The treatment was well tolerated and resulted in a fast parasite and fever clearance. However, the high rate of recrudescence precludes the use of fosmidomycin as a monotherapy. In drug combination studies, synergy of fosmidomycin with clindamycin was observed. Clinical studies with a fosmidomycin-clindamycin combination are currently ongoing.

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Jochen Wiesner
    • 1
  • Steffen Borrmann
    • 2
  • Hassan Jomaa
    • 1
  1. 1.Jomaa Pharmaka GmbH, Frankfurter Strasse 50, 35392 Gießen, Germany
  2. 2.Department of Parasitology, Institute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany